Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 131

1.

259PDTHE 12-GENE DCIS SCORE ASSAY AND QUANTITATIVE ER, PR, AND HER2 ACROSS HISTOLOGIC SUBTYPES: EXPERIENCE IN THE FIRST 2 YEARS.

Sing A, Tan V, Bailey H, Anderson JM, Rothney M, Baehner FL.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv87. doi: 10.1093/annonc/mdu327.7. No abstract available.

PMID:
28172209
2.

814PDGENOMIC RENAL SCORE FOR ASSESSING RISK OF RECURRENCE IN RENAL CANCER: SUBGROUP ANALYSES FROM THE VALIDATION STUDY.

Escudier B, Koscielny S, Lopatin M, Svedman C, Verkarre V, Radulescu C, Neuzillet Y, Timsit M, Hemmerlé I, Tsiatis T, Bonham M, Knezevic D, Lebret T, Goddard A, Mejean A.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv282-iv283. doi: 10.1093/annonc/mdu337.7. No abstract available.

PMID:
28172030
3.

287PA LABORATORY COMPARISON OF THE 21-GENE ASSAY AND PAM50-ROR.

Alvarado M, Prasad C, Rothney M, Cherbavaz D, Sing A, Svedman C, Markopoulos C.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv96. doi: 10.1093/annonc/mdu327.33. No abstract available.

PMID:
28171970
4.

261PDTHE EFFECT OF PHYSICIAN'S CHARACTERISTICS ON ADJUVANT CHEMOTHERAPY (CT) DECISIONS FOR EARLY STAGE HR + , HER2- BREAST CANCER (BC) PATIENTS (PTS).

De Laurentiis M, Aapro M, Markopoulos C, Mamounas T, Rouzier R, Thomssen C, Rocha JE, Rea D, Neven P, Linderholm B, Smit V, Landherr L, Petrovsky A, Svedman C, Martin M.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv88. doi: 10.1093/annonc/mdu327.9. No abstract available.

PMID:
28170823
5.

295PTRADITIONAL PROGNOSTIC FACTORS USED FOR ADJUVANT CHEMOTHERAPY (CT) DECISIONS IN EARLY STAGE HR + , HER2- BREAST CANCER IN A LARGE INTERNATIONAL SURVEY (MAGIC) AMONG BREAST CANCER SPECIALISTS.

Martin M, Aapro M, Markopoulos C, Mamounas T, Rouzier R, Thomssen C, Rocha JE, Rea D, Neven P, Linderholm B, Smit V, Landherr L, Petrovsky A, Svedman C, De Laurentiis M.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv98-iv99. doi: 10.1093/annonc/mdu327.41. No abstract available.

PMID:
28170712
6.

288PIMPACT OF THE 21-GENE BREAST CANCER ASSAY ON TREATMENT RECOMMENDATIONS FOR ESTROGEN RECEPTOR-POSITIVE (ER+) EARLY STAGE BREAST CANCER (ESBC) IN HONG KONG.

Leung R, Yau T, Chao C, Yoshizawa C, Cheung P.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv96. doi: 10.1093/annonc/mdu327.34. No abstract available.

PMID:
28170704
7.

174PPREDICTION OF RECURRENCE WITH THE RECURRENCE SCORE IN PRE- AND POST-MENOPAUSAL PATIENTS FROM THE PACS01 TRIAL.

Penault-Llorca F, Filleron T, Asselain B, Baehner F, Fumoleau P, Lacroix-Triki M, Butler S, Jamshidian F, Cherbavaz D, Roca L, Sagan C, Lemonnier J, Martin A, Roche H.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv60-iv61. doi: 10.1093/annonc/mdu326.8. No abstract available.

PMID:
28170686
8.

177PRECURRENCE SCORE AND QUANTITATIVE ER EXPRESSION PREDICTS LATE DISTANT RECURRENCE RISK IN ER+ BC AFTER FIVE YEARS OF TAMOXIFEN.

Mamounas T, Wolmark N, Baehner F, Butler S, Tang G, Jamshidian F, Sing A, Shak S, Paik S.

Ann Oncol. 2014 Sep 1;25(suppl_4):iv61. doi: 10.1093/annonc/mdu326.11. No abstract available.

PMID:
28170651
9.

The development of the DCIS score: Scaling and normalization in the Marin General Hospital cohort.

Butler SM, Yoshizawa CN, Prasad C, Cherbavaz DB, Jamshidian F, Shak S.

J Clin Oncol. 2012 Sep 20;30(27_suppl):190. doi: 10.1200/jco.2012.30.27_suppl.190.

PMID:
28146833
10.

Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.

Tang G, Paik S, Baehner FL, Liu Q, Jeong JH, Kim SR, Butler SM, Jamshidian F, Cherbavaz DB, Shak S, Julian TB, Lembersky BC, Wickerham DL, Costantino JP, Wolmark N.

J Clin Oncol. 2012 Sep 20;30(27_suppl):1. doi: 10.1200/jco.2012.30.27_suppl.1.

PMID:
28146698
11.

Identification of prostate cancer-expressed microRNAs associated with clinical recurrence (cR) and prostate cancer-specific survival (PCSS) following radical prostatectomy (RP).

Klein EA, Kiefer M, Crager M, Magi-Galluzzi C, Falzarano SM, Pelham RJ, Millward C, Cherbavaz DB, Baker J, Shak S, Lee M.

J Clin Oncol. 2012 Feb 10;30(5_suppl):21. doi: 10.1200/jco.2012.30.5_suppl.21.

PMID:
28142917
12.

The 21-gene breast cancer assay in small (<1cm) tumors.

Stoppler MC, Rothney M, Sing AP.

J Clin Oncol. 2014 Sep 10;32(26_suppl):33. doi: 10.1200/jco.2014.32.26_suppl.33.

PMID:
28141144
13.

21-gene Recurrence Score testing and subsequent treatment decisions in patients (pts) with estrogen-receptor-positive (ER+) early-stage breast cancer (ESBC).

Burkhart J, Campbell D, Devitt JJ, Vacchino J, Sing AP.

J Clin Oncol. 2013 Sep 10;31(26_suppl):30. doi: 10.1200/jco.2013.31.26_suppl.30.

PMID:
28136630
14.

Quantitative gene expression by RT-PCR in classic and variant lobular carcinoma in ER+ breast cancer.

Yoshizawa CN, Watson D, Tan V, Bailey H, Tsiatis AC, Shak S, Baehner FL.

J Clin Oncol. 2013 Sep 10;31(26_suppl):11. doi: 10.1200/jco.2013.31.26_suppl.11.

PMID:
28136589
15.

Quantitative gene expression by RT-PCR in the tubular, cribriform, mucinous, and papillary histologic subtypes of invasive breast cancer.

Yoshizawa CN, Anderson JM, Shak S, Baehner FL.

J Clin Oncol. 2013 Sep 10;31(26_suppl):10. doi: 10.1200/jco.2013.31.26_suppl.10.

PMID:
28136583
16.

A nonrandomized observational trial of short-term preoperative endocrine therapy in ER-positive breast cancer to investigate change in genomic expression using the 21-gene breast cancer assay.

Bleznak AD, Dellers EA, Glenn-Porter B, Kimmel S, Chung H, Yoshizawa C, Burke E, Davison DS, Chao C.

J Clin Oncol. 2011 Sep 20;29(27_suppl):221.

PMID:
27958117
17.

Evaluation of recurrence score and traditional clinicopathologic metrics in a large ER-positive, lymph node-negative patient cohort.

Baehner FL, Liebermann N, Shak S, Klang S, Yoshizawa C, Lior S, Siegelmann-Danieli N.

J Clin Oncol. 2011 Sep 20;29(27_suppl):30.

PMID:
27957997
18.

Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2-3) and Implications for Risk Stratification: A Systematic Review.

Kane CJ, Eggener SE, Shindel AW, Andriole GL.

Eur Urol Focus. 2017 Mar 11. pii: S2405-4569(16)30157-2. doi: 10.1016/j.euf.2016.10.010. [Epub ahead of print] Review.

PMID:
28753804
19.

Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop.

Hughes KS, Ambinder EP, Hess GP, Yu PP, Bernstam EV, Routbort MJ, Clemenceau JR, Hamm JT, Febbo PG, Domchek SM, Chen JL, Warner JL; OPO Workshop Members.

J Clin Oncol. 2017 Jul 24:JCO2017741744. doi: 10.1200/JCO.2017.74.1744. [Epub ahead of print]

PMID:
28737972
20.

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study.

Petkov VI, Miller DP, Howlader N, Gliner N, Howe W, Schussler N, Cronin K, Baehner FL, Cress R, Deapen D, Glaser SL, Hernandez BY, Lynch CF, Mueller L, Schwartz AG, Schwartz SM, Stroup A, Sweeney C, Tucker TC, Ward KC, Wiggins C, Wu XC, Penberthy L, Shak S.

NPJ Breast Cancer. 2016 Jun 8;2:16017. doi: 10.1038/npjbcancer.2016.17. eCollection 2016.

Supplemental Content

Loading ...
Support Center